Microba completes dosing in Phase I IBD Clinical Trial
Microba Life Sciences today announced that all participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba's The...
“Testing, understanding and modifying the microbiome is key to addressing many diseases and improving our health. Microba’s leading technology is driving this health transformation.”
— Professor Ian Frazer, Chair of Medical Advisory Board